))
🧬 Mark Kotter - bit.bio - Part 4 | Democratizing Access to Cells & the Evolution of bit.bio | A Financial Journey from Angel Investment to IPO | Building a Tech Bio Platform & Mark’s 10-Year Vision
Manage episode 425889133 series 3461709
Contenuto fornito da Jon Chee. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Jon Chee o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Part 4 of 4.
My guest for this week’s episode is Mark Kotter, neurosurgeon, stem cell biologist, and CEO and founder of bit.bio. He has also been a professor and researcher at Cambridge for more than 15 years.
Bit.bio is an award-winning human synthetic biology company providing human cells for research, drug discovery, and cell therapy. The company applies a patented safe harbor gene targeting approach to inducibly express transcription factor combinations that reprogram human-induced pluripotent stem cells into highly defined and mature human cell types. Bit.bio spun out of the University of Cambridge in 2016 and has since raised approximately $200 million from Arch Ventures, Foresight Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, and Pulau Capital, among others.
Mark is also the co-founder of Meatable, scientific founder and chairman of rejuvenation startup clock.bio, and co-founder and trustee of Myelopathy.org, the first charity dedicated to a common yet often overseen condition causing a slow-motion spinal cord injury. His diverse experience as an academic and serial entrepreneur offers a wealth of insights aspiring scientist founders can draw from.
Join us this week and hear about:
- The evolution of bit.bio and their mission to democratize access to human cells and therapies
- Building a solid infrastructure and hiring the right people
- The early hurdles of securing funding and managing co-founder dynamics and bit.bio’s financial journey from angel investments to institutional funding
- Mark’s plans to take the company public
Please enjoy my conversation with Mark Kotter.
Timestamps
00:28 Intro
01:52 Democratizing access to cells, the core mission of bit.bio
04:06 A new paradigm of creating batches of cells
06:26 Creating a new market out of a disruptive product
09:20 The business initiatives at bit.bio and Mark’s driving philosophies
11:28 The journey of new modality platforms like bit.bio’s & the IP landscape
15:02 Building the infrastructure and engine powering bit.bio, finding the right people
23:05 Financing bit.bio early on and their financial journey from a small, scrappy lab
26:56 Raising larger funds from institutional investors, bit.bio’s Series A and B
28:56 Mark’s future plans and 10-year vision for bit.bio
31:16 The 2-year vision, what will happen at bit.bio in the near future
34:16 Shout outs and advice to 21-year old self
36:05 Outro
Find Our Guest, Mark Kotter, at these links:
Find Our Host, Jon Chee, at these links:
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Topics Mentioned:
bit.bio https://www.bit.bio/
Charles River Laboratories https://www.criver.com/
Meatable https://meatable.com/
University of Cambridge https://www.cam.ac.uk/
GMP (Good Manufacturing Practice) https://www.excedr.com/resources/gmp-vs-glp-whats-the-difference
Intellectual Property Strategy in Biotech https://www.excedr.com/resources/intellectual-property-strategy-for-biotechs
Patents in Biotech https://www.excedr.com/resources/intellectual-property-rights-for-biotechs
Partnerships in Biotech https://www.excedr.com/blog/how-biotech-partnerships-support-research
Genetic Engineering https://medicine.missouri.edu/centers-institutes-labs/health-ethics/faq/gene-therapy
People Mentioned:
Shinya Yamanaka https://en.wikipedia.org/wiki/Shinya_Yamanaka
Kathryn Penkus Corzo https://www.linkedin.com/in/kathryn-penkus-corzo/
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
56 episodi
Condividi
